Korean J Gastroenterol.  2022 Aug;80(2):72-76. 10.4166/kjg.2022.086.

Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease

• Jin BC
• Moon HJ
• Kim SW

• KMID: 2532681
• DOI: http://doi.org/10.4166/kjg.2022.086

Abstract

Latent tuberculosis (TB) infections (LTBI) impose clinical challenges in terms of the diagnosis and treatment of inflammatory bowel disease (IBD), especially in TB-endemic areas. While steroids and biologics have become increasingly useful in the treatment of patients with moderate-to-severe IBD, the risk of reactivation or developing TB is increased due to their potent immunosuppressive effects. Tumor necrosis factor-alpha inhibition may result in the activation of a latent TB infection, and most cases manifest as more severe forms of disseminated TB. All potential users of immunosuppressive therapy should be screened for LTBI, and appropriate measures for the management of latent and active TB should be undertaken with immediate initiation of anti-TB treatment. Biologics should be withheld during TB treatment, and the proper timing for the resumption of IBD therapy during or after TB treatment should be individualized. This review summarizes the latest knowledge on the risk assessment, detection, and management of latent and active TB infections in patients with IBD.

Keyword

Inflammatory bowel disease; Latent tuberculosis; Tuberculosis infection; Biological therapy

Figure

• 

  Fig. 1 Algorithm for the diagnosis of latent tuberculosis infection in patients with IBD. IBD, inflammatory bowel disease; Sx, symptom; CXR, chest X-ray; TST, tuberculin skin test; IGRA, interferon-γ releasing assay; LBTI, latent tuberculosis infection.

Reference

1. Sood A, Kaur K, Mahajan R, et al. 2021; Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res. 19:206–216. DOI: 10.5217/ir.2019.09169. PMID: 32646197. PMCID: PMC8100380.

2. Rustgi SD, Kayal M, Shah SC. 2020; Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 13:1756284820915043. DOI: 10.1177/1756284820915043. PMID: 32523620. PMCID: PMC7236567.

3. Geuking MB, Köller Y, Rupp S, McCoy KD. 2014; The interplay between the gut microbiota and the immune system. Gut Microbes. 5:411–418. DOI: 10.4161/gmic.29330. PMID: 24922519. PMCID: PMC4153781.

4. Banerjee R, Ali RAR, Wei SC, Adsul S. 2020; Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries. Gut Liver. 14:685–698. DOI: 10.5009/gnl19209. PMID: 33191310. PMCID: PMC7667923.

5. Shim TS, Koh WJ, Yim JJ, Lew WJ. 2004; Diagnosis and treatment of latent tuberculosis infection in Korea. Tuberc Respir Dis. 57:101–117. DOI: 10.4046/trd.2004.57.2.101.

6. 2021 annual report on the notified tuberculosis in Korea. [Internet]. Cheongju: Korea Disease Control and Prevention Agency;2021. cited 2022 Jul 19. Available from: https://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=1&pblctDtaSn=2598.

7. Kucharzik T, Ellul P, Greuter T, et al. 2021; ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 15:879–913. DOI: 10.1093/ecco-jcc/jjab052. PMID: 33730753.

8. Alrajhi S, Germain P, Martel M, et al. 2020; Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease. Intest Res. 18:306–314. DOI: 10.5217/ir.2019.00116. PMID: 32182640. PMCID: PMC7385575.

9. Goletti D, Sanduzzi A, Delogu G. 2014; Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl. 91:24–31. DOI: 10.3899/jrheum.140099. PMID: 24788997.

10. Korean guidelines for tuberculosis. [Internet]. Seoul: The Korean Academy Of Tuberculosis And Respiratory Diseases;2020. cited 2022 Jul 19. Available from: https://www.lungkorea.org/bbs/index.html?code=guide&category=&gubun=&page=1&number=10303&mode=view&keyfield=&key=.

11. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. [Internet]. London: National Institute for Health and Clinical Excellence (UK);2011. cited 2022 Jul 19. Available from: https://www.ncbi.nlm.nih.gov/books/NBK97852/.

12. Bonovas S, Fiorino G, Allocca M, et al. 2016; Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 14:1385–1397.e10. DOI: 10.1016/j.cgh.2016.04.039. PMID: 27189910.

13. Maaser C, Sturm A, Vavricka SR, et al. 2019; ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 13:144–164. DOI: 10.1093/ecco-jcc/jjy113. PMID: 30137275.

14. Lorenzetti R, Zullo A, Ridola L, et al. 2014; Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med. 46:547–554. DOI: 10.3109/07853890.2014.941919. PMID: 25105206.

15. Bogas M, Machado P, Mourão AF, et al. 2010; Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. Clin Rheumatol. 29:629–635. DOI: 10.1007/s10067-010-1380-z. PMID: 20140758.

16. Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. 2013; Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol. 69:25–33. DOI: 10.1016/j.jaad.2012.12.966. PMID: 23375515.

17. Rahier JF, Ben-Horin S, Chowers Y, et al. 2009; European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 3:47–91. DOI: 10.1016/j.crohns.2009.02.010. PMID: 21172250.

18. Cohn DL, O'Brien RJ, Geiter LJ, et al. 2000; Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 49:1–54. DOI: 10.1037/e548072006-001. PMID: 32053584. PMCID: PMC7041302.

19. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982; 60:555–564. PMID: 6754120. PMCID: PMC2536088.

20. Park DI, Hisamatsu T, Chen M, et al. 2018; Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management. J Gastroenterol Hepatol. 33:30–36. DOI: 10.1111/jgh.14018. PMID: 29024102.

21. Korean Association for the Study of Intestinal Diseases. Inflammatory bowel disease. Seoul: Medbook;2016.

22. Hibi T, Kamae I, Pinton P, et al. 2021; Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intest Res. 19:53–61. DOI: 10.5217/ir.2019.09146. PMID: 32312035. PMCID: PMC7873404.

23. Tubach F, Salmon D, Ravaud P, et al. 2009; Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60:1884–1894. DOI: 10.1002/art.24632. PMID: 19565495. PMCID: PMC2921546.

24. Singh JA, Wells GA, Christensen R, et al. 2011; Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011:CD008794. DOI: 10.1002/14651858.CD008794.pub2. PMCID: PMC7173749. PMID: 21328309.

25. Ford AC, Peyrin-Biroulet L. 2013; Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 108:1268–1276. DOI: 10.1038/ajg.2013.138. PMID: 23649185.

26. Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. 2021; Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res. 19:419–429. DOI: 10.5217/ir.2020.00033. PMID: 33166442. PMCID: PMC8566831.

27. British Thoracic Society Standards of Care Committee. 2005; BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 60:800–805. DOI: 10.1136/thx.2005.046797. PMID: 16055611. PMCID: PMC1747200.

28. Cagatay T, Bingol Z, Kıyan E, et al. 2018; Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: tuberculin skin test conversion and tuberculosis risk. Clin Respir J. 12:1668–1675. DOI: 10.1111/crj.12726. PMID: 29028148.

29. Abitbol Y, Laharie D, Cosnes J, et al. 2016; Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohns Colitis. 10:1179–1185. DOI: 10.1093/ecco-jcc/jjw129. PMID: 27402916.

30. Limsrivilai J, Pausawasdi N. 2021; Intestinal tuberculosis or Crohn's disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intest Res. 19:21–32. DOI: 10.5217/ir.2019.09142. PMID: 32311862. PMCID: PMC7873401.